Cocrystal Applications in Drug Delivery

In 2015, the first pharmaceutical cocrystal was approved by the FDA. Since then, the number of cocrystals on the market and in the development pipeline has been slowly but steadily growing. It is now well established that cocrystals are a versatile new approach to oral drug formulation. This Reprint...

Full description

Saved in:
Bibliographic Details
Other Authors: Erxleben, Andrea (Editor)
Format: Book Chapter
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03503naaaa2200913uu 4500
001 doab_20_500_12854_68386
005 20210501
020 |a books978-3-03943-984-3 
020 |a 9783039439836 
020 |a 9783039439843 
024 7 |a 10.3390/books978-3-03943-984-3  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a GP  |2 bicssc 
100 1 |a Erxleben, Andrea  |4 edt 
700 1 |a Erxleben, Andrea  |4 oth 
245 1 0 |a Cocrystal Applications in Drug Delivery 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (172 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a In 2015, the first pharmaceutical cocrystal was approved by the FDA. Since then, the number of cocrystals on the market and in the development pipeline has been slowly but steadily growing. It is now well established that cocrystals are a versatile new approach to oral drug formulation. This Reprint Book is a collection of articles that show the utility of pharmaceutical cocrystals and various aspects of cocrystal research: • Cocrystals as a strategy to modify the physicochemical properties of a drug such as dissolution behaviour, tabletability, and melting point; • Development of new coformers; • Screening studies for multiple cocrystal forms; • Cocrystals in nano-sized drug delivery. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
653 |a nitazoxanide 
653 |a cocrystals 
653 |a multicomponent crystals 
653 |a dissolution behavior 
653 |a supersaturated formulations 
653 |a crystallization inhibitors 
653 |a drug-polymer interactions 
653 |a nano co-crystals 
653 |a crystal engineering 
653 |a polydispersity index 
653 |a zeta potential 
653 |a particle size 
653 |a zidovudine 
653 |a lamivudine 
653 |a HIV/AIDS 
653 |a sonochemistry 
653 |a imidazole N-oxides 
653 |a barbituric acid 
653 |a thiobarbituric acid 
653 |a pharmaceutical cocrystals 
653 |a mechanochemistry 
653 |a solid state NMR 
653 |a X-ray Diffraction 
653 |a design of experiments 
653 |a Quality by Design 
653 |a cocrystal 
653 |a compaction 
653 |a nanoindentation 
653 |a slip plane 
653 |a tabletability 
653 |a surface topology 
653 |a interparticulate bonding area 
653 |a interparticulate bonding strength 
653 |a nefiracetam 
653 |a solid state 
653 |a solubility 
653 |a dissolution rate 
653 |a stability 
653 |a formulation 
653 |a diclofenac sodium 
653 |a L-proline 
653 |a salt cocrystal 
653 |a multicomponent crystal 
653 |a monohydrate 
653 |a tetrahydrate 
653 |a dissolution 
653 |a itraconazole 
653 |a terephthalic acid 
653 |a crystal structure 
653 |a solid-state 
653 |a thermal analysis 
653 |a wettability 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/3399  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/68386  |7 0  |z DOAB: description of the publication